Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.78 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.78 |
| ▸ | RAB9A | P51151 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 6/20 | 0.78 |
| ▸ | HTT | P42858 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.69 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1874466 | 0.95 | LMNA (0.72) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL13297977 | 0.85 | SLC12A2 (0.92) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL3079952 | 0.85 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL28001439 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL19264910 | 0.85 | SLC12A2 (0.92) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL4763389 | 0.85 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL1423782 | 0.85 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL22639673 | 0.84 | LMNA (1.00) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL22639799 | 0.84 | LMNA (1.00) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA | |
| SCHEMBL10282764 | 0.83 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2NR2F2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| EP-3134397-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2017-03-01 | — | — | EP | disclosed |
| EP-3134396-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| WO-2015162459-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015162456-A1 | AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1307458-A1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002012246-A1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | ALDH1A1 3615/4885SMN1; SMN2 4128/4885NR2F2 4001/4885 |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP5K1B, PIP4K2B | ALDH1A1 3615/4885SMN1; SMN2 4128/4885NR2F2 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.